JP2018532432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532432A5 JP2018532432A5 JP2018543073A JP2018543073A JP2018532432A5 JP 2018532432 A5 JP2018532432 A5 JP 2018532432A5 JP 2018543073 A JP2018543073 A JP 2018543073A JP 2018543073 A JP2018543073 A JP 2018543073A JP 2018532432 A5 JP2018532432 A5 JP 2018532432A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric receptor
- domain
- signaling domain
- derived
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108700010039 chimeric receptor Proteins 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 49
- 230000011664 signaling Effects 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 25
- 230000004068 intracellular signaling Effects 0.000 claims description 21
- 101150013553 CD40 gene Proteins 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 108020001756 ligand binding domains Proteins 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 15
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 230000000139 costimulatory effect Effects 0.000 claims description 14
- 230000001086 cytosolic effect Effects 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- -1 EGP2 Proteins 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 125000006850 spacer group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 8
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 6
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims description 5
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 4
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 4
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 4
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 101150047061 tag-72 gene Proteins 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims description 2
- 108050006400 Cyclin Proteins 0.000 claims description 2
- 108010060273 Cyclin A2 Proteins 0.000 claims description 2
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 2
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 2
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 2
- 102100038595 Estrogen receptor Human genes 0.000 claims description 2
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 2
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 101800001271 Surface protein Proteins 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 2
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 2
- 229960004373 acetylcholine Drugs 0.000 claims description 2
- 230000003432 anti-folate effect Effects 0.000 claims description 2
- 229940127074 antifolate Drugs 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 229940014144 folate Drugs 0.000 claims description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 102000003998 progesterone receptors Human genes 0.000 claims description 2
- 108090000468 progesterone receptors Proteins 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 4
- 102000000763 Survivin Human genes 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 8
- 230000007730 Akt signaling Effects 0.000 description 4
- 102100026497 Zinc finger protein 654 Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 230000030570 cellular localization Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 101000959884 Ascaris suum Major pepsin inhibitor 3 Proteins 0.000 description 2
- 102100023795 Elafin Human genes 0.000 description 2
- 101001048718 Homo sapiens Elafin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562251590P | 2015-11-05 | 2015-11-05 | |
| US62/251,590 | 2015-11-05 | ||
| PCT/US2016/060736 WO2017079705A1 (en) | 2015-11-05 | 2016-11-04 | Chimeric receptors containing traf-inducing domains and related compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018532432A JP2018532432A (ja) | 2018-11-08 |
| JP2018532432A5 true JP2018532432A5 (enExample) | 2019-12-12 |
Family
ID=57543143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543073A Ceased JP2018532432A (ja) | 2015-11-05 | 2016-11-04 | Ｔｒａｆ誘導ドメインを含有するキメラ受容体ならびに関連する組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180319862A1 (enExample) |
| EP (1) | EP3370762A1 (enExample) |
| JP (1) | JP2018532432A (enExample) |
| KR (1) | KR20180082493A (enExample) |
| CN (1) | CN108472346A (enExample) |
| AU (1) | AU2016349724B2 (enExample) |
| BR (1) | BR112018008442A2 (enExample) |
| CA (1) | CA3002990A1 (enExample) |
| MA (1) | MA44314A (enExample) |
| MX (1) | MX2018005618A (enExample) |
| WO (1) | WO2017079705A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| CN107530424A (zh) | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| CN108367057B (zh) | 2015-04-06 | 2022-11-22 | 赛通免疫股份有限公司 | 用于胶质母细胞瘤的egfr导向的car疗法 |
| EP3368571B1 (en) | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| WO2018064076A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
| BR112020005552A2 (pt) | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| DK3688032T3 (da) | 2017-09-26 | 2025-12-15 | Cero Therapeutics Holdings Inc | Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder |
| JP7414714B2 (ja) * | 2017-09-29 | 2024-01-16 | ナショナル ヘルス リサーチ インスティテューツ | 抗腫瘍および抗ウイルスｔ細胞の生存および機能性を増強する方法および組成物 |
| KR102774451B1 (ko) * | 2017-11-14 | 2025-02-28 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| KR20200131844A (ko) * | 2018-03-16 | 2020-11-24 | 사이토이뮨 테라퓨틱스 인코퍼레이티드 | 이중특이적 항체 car 세포 면역요법 |
| RU2020135107A (ru) | 2018-03-28 | 2022-04-29 | Серо Терапьютикс, Инк. | Клеточные иммунотерапевтические композиции и их применения |
| US12291557B2 (en) | 2018-03-28 | 2025-05-06 | Cero Therapeutics Holdings, Inc. | Chimeric TIM4 receptors and uses thereof |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020033464A1 (en) | 2018-08-07 | 2020-02-13 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t-cells for the treatment of bone metastatic cancer |
| US12569507B2 (en) * | 2018-08-07 | 2026-03-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T-cells for the treatment of bone metastatic cancer |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| ES3068417T3 (en) | 2018-09-13 | 2026-05-29 | Nkarta Inc | Natural killer cell compositions and immunotherapy methods for treating a liver tumor |
| WO2020085480A1 (ja) * | 2018-10-26 | 2020-04-30 | キッセイ薬品工業株式会社 | 高効率な遺伝子改変細胞の作製方法 |
| JP7863702B2 (ja) * | 2018-11-08 | 2026-05-22 | セルキュア インコーポレイテッド | 表現型特性が向上したｔ細胞組成物 |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク． | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| KR20210132668A (ko) * | 2019-02-21 | 2021-11-04 | 아르벨 리미티드 | 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN118165120A (zh) * | 2019-07-22 | 2024-06-11 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| US20220265715A1 (en) * | 2019-07-24 | 2022-08-25 | Eureka Therapeutics, Inc. | Chimeric antigen receptor t cells and uses thereof |
| WO2021019706A1 (ja) * | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| CN112390894A (zh) * | 2019-08-12 | 2021-02-23 | 广东东阳光药业有限公司 | 嵌合抗原受体及其应用 |
| WO2021048850A1 (en) * | 2019-09-11 | 2021-03-18 | Migal Galilee Research Institute, Ltd. | Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereof |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| CN112251452A (zh) * | 2019-10-22 | 2021-01-22 | 上海斯丹赛生物技术有限公司 | Til/tcr-t细胞治疗平台 |
| WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| JP7439279B2 (ja) * | 2020-02-13 | 2024-02-27 | イミュノファーム テクノロジー カンパニー リミテッド | キメラ抗原受容体の最適化 |
| CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN111849910B (zh) | 2020-05-27 | 2021-06-15 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| CN116348485A (zh) | 2020-07-17 | 2023-06-27 | 英研生物(英国)有限公司 | 提供用于过继性细胞疗法的靶向共刺激的受体 |
| WO2022016114A1 (en) * | 2020-07-17 | 2022-01-20 | Instill Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
| JP7868033B2 (ja) | 2020-08-14 | 2026-06-01 | セロ・セラピューティクス・ホールディングス・インコーポレイテッド | キメラｔｉｍ受容体およびその使用 |
| EP4097486A4 (en) | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER |
| US11433100B2 (en) | 2020-08-20 | 2022-09-06 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| WO2022040454A1 (en) | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| EP4058474B1 (en) | 2020-08-20 | 2024-05-08 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| WO2022051386A2 (en) * | 2020-09-02 | 2022-03-10 | The Regents Of The University Of California | Chimeric receptors with diverse co-regulatory sequences |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| EP4251176A4 (en) * | 2020-11-24 | 2025-01-15 | A2 Biotherapeutics, Inc. | Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| TW202306997A (zh) * | 2021-06-16 | 2023-02-16 | 英商英斯特生物科技有限公司 | 用於在過繼細胞療法中提供標靶共刺激之受體 |
| WO2022272283A1 (en) * | 2021-06-24 | 2022-12-29 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Dual egfr-muc1 chimeric antigen receptor t cells |
| EP4370213A4 (en) * | 2021-07-16 | 2025-06-04 | Instil Bio (Uk) Limited | Chimeric molecules for targeted costimulation for adoptive cell therapy |
| WO2023020472A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Mesothelin-targetting antibodies and uses thereof in cancer therapies |
| EP4502162A4 (en) * | 2022-03-29 | 2026-03-18 | Univ Jichi Medical | SELECTIVE GENE REGULATION SYSTEM (SRG) FOR GENETICALLY MODIFIED IMMUNE CELL THERAPY |
| CN119301149A (zh) * | 2022-03-30 | 2025-01-10 | 海岸线生物科学公司 | 自然杀伤细胞的嵌合抗原受体及其在免疫疗法中的用途 |
| EP4504245A1 (en) * | 2022-04-07 | 2025-02-12 | Institut Curie | Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy |
| US20250222106A1 (en) * | 2022-04-07 | 2025-07-10 | Institut Curie | Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy |
| WO2024091669A1 (en) * | 2022-10-28 | 2024-05-02 | Ginkgo Bioworks, Inc. | Chimeric antigen receptors comprising an intracellular domain pair |
| CN120712345A (zh) * | 2022-12-30 | 2025-09-26 | 上药生物治疗（香港）有限公司 | 表达趋化因子受体的细胞及其用途 |
| WO2025212519A1 (en) | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2520643B8 (en) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| ES2785081T3 (es) | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| BR112014020502A2 (pt) * | 2012-02-22 | 2019-09-24 | Univ Pennsylvania | sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| NZ702108A (en) | 2012-05-03 | 2016-09-30 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| CA2905352A1 (en) * | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| EP3097117B1 (en) * | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
-
2016
- 2016-11-04 MX MX2018005618A patent/MX2018005618A/es unknown
- 2016-11-04 AU AU2016349724A patent/AU2016349724B2/en not_active Ceased
- 2016-11-04 MA MA044314A patent/MA44314A/fr unknown
- 2016-11-04 EP EP16810123.6A patent/EP3370762A1/en not_active Withdrawn
- 2016-11-04 WO PCT/US2016/060736 patent/WO2017079705A1/en not_active Ceased
- 2016-11-04 US US15/773,540 patent/US20180319862A1/en not_active Abandoned
- 2016-11-04 CN CN201680077930.4A patent/CN108472346A/zh active Pending
- 2016-11-04 CA CA3002990A patent/CA3002990A1/en not_active Abandoned
- 2016-11-04 BR BR112018008442A patent/BR112018008442A2/pt not_active Application Discontinuation
- 2016-11-04 JP JP2018543073A patent/JP2018532432A/ja not_active Ceased
- 2016-11-04 KR KR1020187015890A patent/KR20180082493A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016349724A1 (en) | Chimeric receptors containing TRAF-inducing domains and related compositions and methods | |
| AU2019229438B2 (en) | Tagged chimeric effector molecules and receptors thereof | |
| Liu et al. | Targeting alpha-fetoprotein (AFP)–MHC complex with CAR T-cell therapy for liver cancer | |
| KR102411571B1 (ko) | 치료제 | |
| JP2024518011A5 (enExample) | ||
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2022512913A5 (enExample) | ||
| JP2020530294A5 (enExample) | ||
| CN111971053A (zh) | 靶向肿瘤微环境的嵌合抗原受体 | |
| JP7566628B2 (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| CN110616191B (zh) | 共刺激配体联合的car t疗法 | |
| JP2021505615A5 (enExample) | ||
| CA3059444A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
| JP2022543742A5 (enExample) | ||
| MD3914611T2 (ro) | Receptori care furnizează costimulare țintită pentru terapia celulară adoptivă | |
| CN114026128A (zh) | 抗原特异性靶向cd19的car-t细胞 | |
| US11332513B2 (en) | Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain | |
| JP2017531687A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2019531328A5 (enExample) | ||
| JP2020535796A5 (enExample) | ||
| JP2021520229A (ja) | 抗ｇｕｃｙ２ｃキメラ抗原受容体の組成物および方法 |